Inovio Pharmaceuticals and vTv Therapeutics Compared

Analysts see more upside potential in Inovio Pharmaceuticals stock

Published on Feb. 24, 2026

Got story updates? Submit your updates here. ›

vTv Therapeutics (NASDAQ:VTVT) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but analysts believe Inovio Pharmaceuticals has more upside potential based on its higher consensus target price. The two companies were compared on factors like analyst recommendations, valuation, institutional ownership, profitability, and other metrics.

Why it matters

The comparison between these two small-cap biotech firms provides insight into their relative strengths and weaknesses for investors considering which stock to add to their portfolio. As both companies work on developing new treatments, understanding their financial performance and market positioning is important.

The details

vTv Therapeutics has a consensus target price of $55.25, suggesting a potential upside of 57.27%. Inovio Pharmaceuticals has a consensus target price of $6.75, suggesting a potential upside of 272.93%. vTv Therapeutics has higher revenue and earnings than Inovio Pharmaceuticals, and is trading at a lower price-to-earnings ratio. However, Inovio Pharmaceuticals has a higher percentage of institutional ownership at 26.8% compared to 17.5% for vTv Therapeutics.

  • The analysis was published on February 24, 2026.

The players

vTv Therapeutics Inc.

A clinical stage biopharmaceutical company focused on developing orally administered treatments for metabolic and inflammatory diseases.

Inovio Pharmaceuticals, Inc.

A biotechnology company that focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with HPV, cancer, and infectious diseases.

Got photos? Submit your photos here. ›

The takeaway

While both companies are small-cap players in the biotech space, the analysis suggests Inovio Pharmaceuticals may have more upside potential based on its higher consensus target price and greater institutional investor interest, despite vTv Therapeutics' stronger financial performance metrics.